BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HIV Pre-Exposure Prophylaxis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in HIV Pre-Exposure Prop
 hylaxis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07044297-1010@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07044297)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Clinical Study of MK-852
 7 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)\nEs
 timated primary completion: 22 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07044297
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071623-1010@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07071623)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Study of MK-8527 to Prev
 ent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)\nEstimated p
 rimary completion: 18 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07071623
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
